Tiaa Fsb boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 7.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 455,841 shares of the company’s stock after acquiring an additional 31,817 shares during the period. Tiaa Fsb’s holdings in Johnson & Johnson were worth $63,690,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares in the last quarter. BlackRock Inc. grew its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after buying an additional 4,332,612 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after buying an additional 130,437 shares in the last quarter. FMR LLC grew its holdings in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after buying an additional 1,509,745 shares in the last quarter. Finally, Capital World Investors grew its holdings in Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock valued at $3,507,009,000 after buying an additional 1,050,000 shares in the last quarter. Institutional investors and hedge funds own 67.18% of the company’s stock.
Shares of JNJ stock opened at $126.76 on Thursday. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a twelve month low of $122.15 and a twelve month high of $148.32. The firm has a market cap of $340,272.47, a P/E ratio of 17.36, a price-to-earnings-growth ratio of 1.94 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.06. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The business had revenue of $20.01 billion during the quarter, compared to the consensus estimate of $19.50 billion. During the same period in the prior year, the company earned $1.83 EPS. Johnson & Johnson’s revenue for the quarter was up 12.6% on a year-over-year basis. research analysts expect that Johnson & Johnson will post 8.13 earnings per share for the current fiscal year.
Several research firms have recently issued reports on JNJ. Zacks Investment Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 target price on the stock in a report on Thursday, April 5th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 target price on the stock in a report on Tuesday, January 23rd. Stifel Nicolaus increased their target price on Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, January 24th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a report on Monday, January 22nd. Finally, Morgan Stanley reduced their target price on Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 10th. Five equities research analysts have rated the stock with a sell rating, eight have given a hold rating and ten have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $142.23.
In related news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a filing with the SEC, which is available through this link. 0.22% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Johnson & Johnson (JNJ) Shares Bought by Tiaa Fsb” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/04/26/johnson-johnson-jnj-shares-bought-by-tiaa-fsb.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.